Clarus Therapeutics Company
Clarus Therapeutics is a biopharmaceutical company that is dedicated to addressing unmet medical needs through the development of androgen replacement and metabolic therapies. It charted a new course for men’s health with JATENZO® (testosterone undecanoate) Capsules CIII, filling a void in the market by developing and launching an oral testosterone replacement therapy.
Technology:
United States
Industry:
Hormonal Health
Headquarters:
Northbrook, Illinois, United States
Founded Date:
2003-01-01
Employees Number:
11-50
Funding Status:
IPO
Investors Number:
4
Total Funding:
$122,000,000
Estimated Revenue:
$10M to $50M
Last Funding Date:
2022-04-25
Last Funding Type:
Post-IPO Equity
Register and Claim Ownership